PDCD1 and pneumonitis: One study showed the occurrence of pneumonitis in 43 out of 915 patients who received anti-PD-1/PD-L1 monoclonal antibodies [7].This case report highlights the importance of recognizing immune-related pneumonitis as a rare but serious adverse effect of nivolumab therapy, having the potential to cause rapid clinical deterioration despite initial apparent improvement.